New Diagnostics and Technology Accelerator (DiTA) leadership appointed
Manchester University NHS Foundation Trust (MFT) has appointed new leadership of its Diagnostics and Technology Accelerator (DiTA).
Read moreResearch and innovation news
Keep up-to-date with the latest news, publications and events from the Research and Innovation team at MFT.
Pandemic affects pregnancy health whether mums catch COVID-19 or not
New global research has found pressures from the COVID-19 pandemic can still take a physical toll on mums-to-be, even if they don’t catch the virus.
Read more
Your Path in Research – Samuel Hey, COVID-19 Research Fellow at North Manchester General Hospital
As part of the NIHR Your Path in Research campaign, Dr Samuel Hey, COVID-19 Clinical Research Fellow at North Manchester General Hospital, shares how COVID-19 sparked his passion for research.
Read more
New study into COVID-19 vaccine dose interval for pregnant women launches in Greater Manchester
The country’s largest clinical study investigating the best gap between first and second COVID-19 vaccine doses for pregnant women has launched in Greater Manchester.
Read more
Rheumatoid Arthritis and predicting the future – Dr Stephanie Ling speaks to Arthritis Digest
Dr Stephanie Ling, Clinical Research Fellow at Manchester Royal Infirmary, discusses working with rheumatoid arthritis patients through research to improve biologic treatments.
Read more
MFT consultant and trainee honoured in prestigious research awards
Two researchers from Manchester University NHS Foundation Trust (MFT) have been named as winners in the Royal College of Physicians (RCP) and National Institute for Health Research (NIHR) Clinical Res
Read more
Advanced clinical risk prediction currently under evaluation at Wythenshawe Hospital could be key for the NHS’s critical care recovery
AI technology developed by Manchester-based start-up Rinicare could free up much needed critical care beds and increase overall surgical capacity
Read more
Early trial of first multivariant COVID-19 vaccine booster begins in Manchester
A phase one trial of one of the world’s first multivariant COVID-19 Vaccine has been launched by US pharmaceutical company Gritstone, in collaboration with MFT.
Read more
